TherapeuticsMD (NASDAQ:TXMD) Releases Earnings Results, Beats Expectations By $6.16 EPS

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings data on Friday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $6.16, FiscalAI reports. The firm had revenue of $1.26 million for the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative net margin of 6.64% and a negative return on equity of 1.09%.

TherapeuticsMD Stock Performance

NASDAQ TXMD traded up $0.05 on Friday, reaching $1.87. 50,241 shares of the company’s stock traded hands, compared to its average volume of 42,189. The firm has a market cap of $21.64 million, a price-to-earnings ratio of 93.50 and a beta of 0.68. The stock has a 50 day moving average price of $1.98 and a 200-day moving average price of $2.09. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $2.95.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States. The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.